Clinical trial
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus…
NCT00177255 · University of Pittsburgh, Other · Terminated
Key facts
| NCT number | NCT00177255 |
|---|---|
| Title | A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers |
| Official title | A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas. |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Aventis Pharmaceuticals Industry Roche Pharma AG |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine |
| Enrollment | 40 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: